+7 (495) 414-60-88

Moscow, 3rd Cherepkovskaya str. 15A

Location map

Prevention of occupational exposure of health care workers.

Finally, the published data on the use of фосфазида in the case of prevention of HIV infection among medical workers.

Were compared the results of post-exposure prophylaxis фосфазидом and zidovudine. Of the 32 people with possible occupational HIV infection фосфазид was appointed 14 medical workers at the age from 23 up to 56 years (3 men, 11 women) as monotherapy in the 0.2 g. 3 times a day for 4 weeks. The comparison group amounted to 18 people from 22 to 63 years (5 men and 13 women)who received ZDV 0.2 g 3 times a day for 4 weeks.

The study of the General blood analysis was conducted on 2-nd and 4-th weeks from the beginning of reception of a preparation with the definition of indicators of the red blood, platelets, leukocytes, and leukocyte formula. In the treatment of фосфазидом of complications and adverse reactions had been reported. On the background of zidovudine 16.7% of patients had a discomfort in the area epigastralna, 11.1% of the total weakness. These phenomena were controlled independently in 5-7 days from the beginning of reception of a preparation. In 22% of persons developed neutropenia and anemia. In monitoring patients of both groups within 1 year no stated objective changes of status: the body temperature was normal, lymph nodes, liver, spleen did not increase, violations on the part of other organs and systems is registered. The results of research in иммуноферментном analysis, immune блотинге on HIV and PCR with the determination of HIV RNA was negative.

Thus, it is shown that in a timely manner the appointed post-exposure prophylaxis, carried out with the help of фосфазида or ZDV, is an effective method, prevent the development of HIV-infection in health care workers after an occupational infection, the absence of undesirable phenomena makes use of фосфазида more attractive.

The low toxicity and good tolerability of the фосфазида, makes it advisable to use it in the following cases:

in the various schemes of HAART,
in the therapy of HIV-infection, in combination with the treatment of chronic hepatitis C and tuberculosis,
for the prevention of HIV transmission from mother to child,
instead of zidovudine during the development of the intolerance of the latter.
The scientific and practical peer-reviewed journal "HIV-infection and immunosuppression, 2012 №2 Volume 4, p-Pb p. 45.